AUTL Autolus Therapeutics plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUTL

Price (delayed)

$2.22

Market cap

$590.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.06

Enterprise value

$785.78M

?
Relative Growth: Rel. Growth: 73
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 8

Autolus Therapeutics plc is a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of ...

Highlights
The company's gross profit has surged by 177% YoY
Autolus Therapeutics's gross margin has surged by 120% YoY
The EPS has declined by 26% year-on-year but it has grown by 2.8% since the previous quarter
Autolus Therapeutics's net income has decreased by 23% YoY but it has increased by 3% QoQ
Autolus Therapeutics's equity has shrunk by 78% YoY and by 31% QoQ
Autolus Therapeutics's quick ratio has decreased by 49% YoY and by 12% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.autolus.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of AUTL

AUTL stock price

How has the Autolus Therapeutics stock price performed over time
Intraday
4.72%
1 week
11%
1 month
50%
1 year
20.65%
YTD
11.56%
QTD
38.75%

Financial performance

How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$117.39M
Gross profit
$18.38M
Operating income
-$246.92M
Net income
-$280.16M
Gross margin
15.7%
Net margin
-238.7%
The company's gross profit has surged by 177% YoY
Autolus Therapeutics's gross margin has surged by 120% YoY
AUTL's operating margin has surged by 77% year-on-year and by 26% since the previous quarter
AUTL's net margin has soared by 69% year-on-year and by 23% since the previous quarter

Price vs fundamentals

How does AUTL's price correlate with its fundamentals

Growth

What is Autolus Therapeutics's growth rate over time

Valuation

What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
7.9
P/S
5.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.69
The EPS has declined by 26% year-on-year but it has grown by 2.8% since the previous quarter
AUTL's price to book (P/B) is 132% higher than its last 4 quarters average of 3.4
Autolus Therapeutics's equity has shrunk by 78% YoY and by 31% QoQ
AUTL's price to sales (P/S) is 96% lower than its 5-year quarterly average of 117.9 and 13% lower than its last 4 quarters average of 5.8
Autolus Therapeutics's revenue has increased by 27% from the previous quarter

Efficiency

How efficient is Autolus Therapeutics business performance
The return on sales has surged by 75% year-on-year and by 25% since the previous quarter
Autolus Therapeutics's return on assets has shrunk by 67% YoY and by 6% QoQ
The return on equity has declined by 39% since the previous quarter
Autolus Therapeutics's ROIC has decreased by 2.4% from the previous quarter and by 2.1% YoY

Dividends

What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUTL.

Financial health

How did Autolus Therapeutics financials performed over time
The company's total assets is 18% higher than its total liabilities
Autolus Therapeutics's quick ratio has decreased by 49% YoY and by 12% QoQ
AUTL's current ratio is down by 42% year-on-year and by 16% since the previous quarter
Autolus Therapeutics's equity has shrunk by 78% YoY and by 31% QoQ
The company's debt to equity rose by 45% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.